Validation of a recombinant based antibody ELISA for diagnosis of human and canine leishmaniasis.
In this study, a recombinant chimeric antigen (CA) ELISA was validated as a single test for both human and dog leishmaniasis. Serum panels included 327 human and 339 canine IFAT-positive and 1113 human and 1078 canine IFAT-negative samples. CA-ELISA was carried out using the same serum dilution, and labelled protein A as secondary reagent. Test performances were calculated using ROC analysis. For the human panel, the test showed diagnostic accuracy (DA) 0.974, specificity (Sp) 97.12%, sensitivity (Se) 91.44%, and concordance (K) 0.88. The dog panel showed DA 0.998, Sp 99.54%, Se 98.54%, and K 0.98. The proposed method is the best recombinant antigen-based ELISA, and can be used as IFAT substitute for mass screening.
Department of Animal Production, Epidemiology and Ecology, Faculty of Veterinary Medicine, University of Torino, Via Leonardo da Vinci 44, 10095 Grugliasco (TO), Italy.
Franco
F
Daprà
Aldo
A
Scalone
Walter
W
Mignone
Ezio
E
Ferroglio
Alessandro
A
Mannelli
Alberto
A
Biglino
Renato
R
Zanatta
Luigi
L
Gradoni
Sergio
S
Rosati
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D004283:Dog Diseases / Q000175:diagnosis* / Q000276:immunology; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D007896:Leishmaniasis / Q000175:diagnosis* / Q000276:immunology / Q000662:veterinary*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012680:Sensitivity and Specificity
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D011993:Recombinant Fusion Proteins